Novartis reported pelacarsen failed its phase III primary endpoint and its stock fell sharply, which reduces the program's commercial prospects and related revenue expectations.
Novartis disclosed that pelacarsen's phase III Lp(a) HORIZON trial did not meet its primary endpoint. The trial failure removed a key potential drug outcome and the stock fell sharply in pre-market trading.
Ionis shares fell in sympathy after Novartis announced the pelacarsen phase III trial missed its primary endpoint, and Novartis holds global rights to the drug.
Follow Novartis AG (NVS) free. When we publish a story about it, you get the plain-English explanation as an alert.
Get alerts for NVS